Repurposing Semaglutide for the Treatment of Cocaine Use Disorder

NCT07227948 on ClinicalTrials.gov · last registry update 2026-03-19

Recruiting now, toward 75 participants. Due to report 28 January 2029, alongside 11 other tracked readouts that quarter. Primary outcome, as filed: Amplitude of the Late Positive Potential (LPP) in microvolts in response to visual stimuli on the Picture Viewing Task. Sponsors move these dates routinely; any movement since this site started watching is listed below. semaglutide is approved in the US, but not for substance use — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status: RECRUITING
Phase: P2
Drug: semaglutide
Ozempic, Rybelsus, Wegovy
Sponsor: The University of Texas Health Science Center, Houston
Sponsor type: Other
Enrollment: 75
Started: 2026-01-15
Primary completion: 2029-01-28 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Amplitude of the Late Positive Potential (LPP) in microvolts in response to visual stimuli on the Picture Viewing Task.

Conditions studied

Cocaine Use Disorder

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.